Drug Profile
Mipetresgene autoleucel - Takara Bio
Alternative Names: NY-ESO-1 antigen-specific RetroNectin® TCR gene therapy - Takara Bio; NY-ESO-1 antigen-specific TCR-gene-transduced autologous lymphocytes - Takara Bio; NY-ESO-1 siTCR gene therapy; NY-ESO-1-antigen-specific-T-cell-receptor-gene-therapy; NY-ESO-1-specific-t-cells; NY-ESO-1-T-cells; NY-ESO-1-TCR; NY-ESO-1-TCR-gene-therapy-Takara; NY-ESO-1-TCR-PBMC; NY-ESO-1-TCR-transduced-lymphocytes; NY-ESO-1-transduced-t-cells; NY-ESO-1-transduced-t-lymphocytes; TBI-1301; TBI-1301ALatest Information Update: 07 Jul 2023
Price :
$50
*
At a glance
- Originator Takara Bio
- Developer Fred Hutchinson Cancer Research Center; Mie University; National Cancer Institute (USA); Takara Bio; University Health Network
- Class Antineoplastics; Gene therapies; Immunotherapies; T lymphocyte cell therapies
- Mechanism of Action Gene transference; Immunologic cytotoxicity; T lymphocyte replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase II Malignant melanoma
- Phase I/II Soft tissue sarcoma; Synovial sarcoma
- Phase I Solid tumours
- No development reported Sarcoma; T-cell lymphoma
Most Recent Events
- 02 Jun 2023 Adverse events and efficacy data from a phase-I/II trial in Synovial sarcoma presented at the 59th Annual Meeting of the American Society of Clinical Oncology (ASCO-2023)
- 06 Dec 2022 Mipetresgene autoleucel is still in phase-I trials for Solid tumours in Canada (Takara Bio pipeline, December 2022)
- 06 Dec 2022 Takara Bio announces intention to submit BLA for Synovial sarcoma in Japan (Takara Bio pipeline, December 2022)